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Abstract
The MUC1 membrane mucin was first identified as the molecule recognised by mouse monoclonal antibodies directed to
epithelial cells, and the cancers which develop from them. Cloning the gene showed that the extracellular domain is made up
of highly conserved repeats of 20 amino acids, the actual number varying between 25 and 100 depending on the allele. Each
tandem repeat contains five potential glycosylation sites, and between doublets of threonines and serines lies an
immunodominant region which contains the epitopes recognised by most of the mouse monoclonal antibodies. The O-
glycans added to the mucin produced by the normal breast are core 2 based and can be complex, while the O-glycans added
to the breast cancer mucin are mainly core 1 based. This means that some core protein epitopes in the tandem repeat which
are masked in the normal mucin are exposed in the cancer associated mucin. Since novel carbohydrate epitopes are also
carried on the breast cancer mucin, the molecule is antigenically distinct from the normal breast mucin. (Changes in
glycosylation in other epithelial cancers have been observed but are not so well documented.) Immune responses to MUC1
have been seen in breast and ovarian cancer patients and clinical studies have been initiated to evaluate the use of antibodies
to MUC1 and of immunogens based on MUC1 for immunotherapy of these patients. The role of the carbohydrates in the
immune response and in other interactions with the effector cells of the immune system is of particular interest and is
discussed. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Historical background
The epithelial mucin which is coded for by the
MUC1 gene is not a classic extracellular complex
mucin such as those found as major components of
the mucous layers covering the gastro-intestinal and
respiratory tracts, but is a transmembrane molecule,
expressed by most glandular epithelial cells. The mol-
ecule was ¢rst identi¢ed in human milk (where it is
shed from the milk secreting epithelial cells), as a
large molecular weight glycoprotein rich in serines,
threonines and prolines carrying a high percentage of
O-linked carbohydrate [1]. It is probably fair to say,
however, that interest in the molecule was dramati-
cally enhanced by cancer researchers using the then
newly developed monoclonal antibody technique to
identify surface molecules on normal epithelial cells,
and the carcinomas which develop from them. Since
the molecule is highly immunogenic in the mouse,
many antibodies were developed to the MUC1 mucin
by various groups using normal or malignant epithe-
lial cells, or their membranes, as immunogens. In
particular, the membrane of the lactating mammary
epithelial cell which surrounds the fat globules shed
into milk was widely used as an immunogen, where
the MUC1 mucin apparently dominates in inducing
antibody responses. The antibodies to this molecule
have been analysed in two ‘wet’ workshops [2,3] as
well as by individual investigators [4^6] so that the
epitopes which they recognise have been extremely
well characterised. Many map to a region between
pairs of serines and threonines within the tandem
repeat (see Fig. 1).
From immunohistochemical staining of tissue sec-
tions with the antibodies it became clear that
although MUC1 is widely expressed by normal
glandular epithelial cells [7], the expression is dra-
matically increased when the cells became malignant.
This has been well documented in breast and ovarian
cancer [8] and available data suggest this is also true
in some lung, pancreatic and prostate cancers [8^10].
The antibody studies also gave the ¢rst indications
that not only is the mucin over-expressed in carcino-
mas, but the pattern of glycosylation is altered. Thus
in the breast cancer mucin, glycosylation changes
result in certain epitopes in the core protein being
exposed which are masked in the mucin produced
by the lactating mammary gland [11]. The antibody
SM3 [12] has been particularly important in de¢ning
this di¡erence, the epitope in the tandem repeat
being accessible in breast cancers, but not in normal
breast [8]. Changes in glycosylation patterns also oc-
cur in other malignancies, as in the colon [13]. How-
ever, the changes are imposed on the normal pattern
of glycosylation, which can be very di¡erent in di¡er-
ent tissues.
Fig. 1. Core protein of the MUC1 mucin. The amino acids in
bold refer to potential O-linked glycosylation sites. 3[ = poten-
tial N-linked glycans.
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Because of the availability of antibodies to the
core protein, the gene coding for this protein was
the ¢rst mucin gene to be cloned [14,15]. The extra-
cellular domain was found to be made up of tandem
repeats (TRs) of 20 amino acids each of which con-
tain ¢ve potential O-glycosylation sites, and TR do-
mains have been found to be a common feature of all
the mucin core proteins for which sequence has been
obtained. A similar strategy of raising antibodies to
the core protein stripped of carbohydrate was used
to clone the cDNAs encoding the core protein of
other mucins. As predicted from previous work, the
gel-forming extracellular mucins (such as MUC2 and
MUC3) are more complex, containing cysteine rich
domains which are involved in oligomerisation as
well as the TR domains for attachment of O-glycans
[16]. MUC4 has recently been fully sequenced and
identi¢ed as the second epithelial mucin which is a
transmembrane molecule [17], and homologous to
the rat sialomucin characterised by Carraway and
colleagues [18]. In the context of target antigens in
cancer, membrane mucins have the advantage of
being accessible to cytotoxic antibodies: The anti-
bodies to the MUC1 mucin have been available since
the early 1980s and clinical studies with these anti-
bodies are beginning to mature. With the availability
of the cDNA coding for the core protein of the
MUC1 mucin, and the characterisation of the
changes in glycosylation which can occur in cancer,
focus is now also being given to the use of antigens
based on MUC1 in ‘active speci¢c immunotherapy,
of cancer patients.
The studies on MUC1 have developed in such a
way as to bring together investigators from several
disciplines including glycobiology, immunology and
oncology. In this article, we will attempt to integrate
data from these di¡erent areas by: (1) reviewing the
data documenting the changes in glycosylation of
MUC1 which can occur in cancer (which also have
relevance to basic changes in O-glycosylation pat-
terns in malignancy); (2) discussing the relevance of
the over-expression and altered glycosylation of
MUC1 to malignant disease and the immune re-
sponse; and (3) summarising the clinical studies
which are being done using antibodies and antigens
based on MUC1 to immunotherapy of cancer pa-
tients.
2. Changes in glycosylation of the MUC1 mucin in
cancer
2.1. The MUC1 core protein
Fig. 1 shows a diagram of the core protein of the
MUC1 mucin indicating the sequence of the tandem
repeat as deduced from the nucleotide sequence. The
extracellular domain is made up largely of 20 amino
acid tandem repeats, the number of which varies with
the allele, making the gene highly polymorphic [19].
The TR domain contains multiple potential O-glyco-
sylation sites and is £anked by degenerate tandem
repeats which also contain such sites, while there
are ¢ve potential N-glycosylation sites closer to the
transmembrane domain [14,15]. Comparison with the
homologous gene in other species shows a high con-
servation of sequence in the transmembrane and cy-
toplasmic domains, while within the tandem repeats
conservation is limited to retaining the sequence as a
sca¡old for the addition of O-glycans [20]. The func-
tion of the highly conserved regions has not been
de¢ned, but it is suggested that these domains may
play a role in signal transduction and in protein in-
teractions. A shorter molecule coded for by a mRNA
where the TR domain has been spliced out may be
more involved in these functions and has been re-
ported to be preferentially expressed in tumours
[21]. In the context of analysing the glycosylation
patterns of MUC1 and its role in inducing an
immune response, clearly the full-length molecule,
which is the dominant form is of central impor-
tance.
2.2. O-Glycosylation in mammalian cells
The addition of N-acetyl galactosamine to serine
or threonine initiates O-glycosylation in mammalian
cells [22]. It is now clear that this reaction is cata-
lysed not by one, but by a family of enzymes (poly-
peptide N-acetylgalactosaminyltransferases) which
show overlapping but di¡erent speci¢cities with re-
gard to peptide sequence [23]. The three GalNAcTs
(GalNAcT1, T2, and T3) which have been speci¢-
cally localised by immunoelectromicroscopy in cells
transfected with the tagged genes, are found distrib-
uted throughout the Golgi apparatus [24], indicating
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that chain initiation may not be restricted to the cis
compartment. O-Glycans are then synthesised by the
addition of sugars individually and sequentially as
the mucin passes through the Golgi. Chains are gen-
erally extended by the addition of polylactosamine
side chains and terminated by the addition of sialic
acid, fucose or galactose. Again it is becoming clear
that more than one enzyme can catalyse the same
speci¢c reaction, and that the same substrate may
be acted on by enzymes which produce di¡erent
products. Thus the sites of glycosylation of the
same core protein could vary depending on the pro-
¢le of expression of GalNAcTs, while the composi-
tion of the O-glycan will be in£uenced both by the
level of activity of a speci¢c glycosyltransferase, and
its position in the Golgi pathway relative to other
enzymes which can compete for the same substrate.
The early work with antibodies indicated that there
were di¡erences in the pattern of O-glycosylation of
MUC1 in breast cancer. These changes could involve
di¡erences in sites of glycosylation or in O-glycan
structure or both.
2.3. Changes in the sites of O-glycosylation of MUC1
in breast cancer
The techniques for analysing speci¢cally the sites
in proteins which are O-glycosylated in vivo have
only recently been developed to the point where
they can be applied to mucin molecules which may
contain hundreds or even thousands of O-glycans
[25]. There are ¢ve potential O-glycosylation sites
in each tandem repeat of MUC1 and the use of these
sites in the normal and malignant mammary gland
has recently been analysed. Analysis of the mucin
produced by the normal lactating mammary gland
has shown that while all of these sites can be glyco-
sylated, the average number of O-glycans added to
each tandem repeat is around 2.5 [26]. Analysis of
the sites of glycosylation of the MUC1 mucin pro-
duced by the breast cancer cell line T47D, however,
suggests that all the ¢ve sites are occupied in all the
tandem repeats (F.G. Hanisch, personal communica-
tion). This di¡erence could be attributable to a di¡er-
ent pro¢le of expression of the GalNAcTs in normal
and malignant mammary tissue. However, initial
analysis of expression of four GalNAcTs in sections
of breast cancers by immunohistochemistry has not
given a clear answer to this point (Burchell and Man-
del, unpublished observations). Another possible ex-
planation is that the O-glycans on the T47D mucin
which are shorter (see below) allow initiation of gly-
cosylation to proceed throughout the Golgi appara-
tus, while the longer side chains which are built on to
the normal mucin block access of the GalNAcTs at a
certain point.
2.4. Changes in the composition of O-glycans added to
MUC1 in breast cancer
In the normal human mammary gland, the addi-
tion of GalNAc to serines or threonines is followed
by the addition of galactose to form core 1 which
then acts as a substrate for the core 2 L1,6GlcNAc T
(C2GnT) enzyme, leading to the formation of core 2
(see Fig. 2). Type II polylactosamine side chains are
then formed and terminated by sialic acid or fucose
[27,28]. Thus the O-glycans on the normally glyco-
sylated mucin are core 2 based. To analyse the struc-
ture of the O-glycans attached to MUC1 produced
by breast cancer cells, the mucin has been labelled,
either internally with 3H-glucosamine hydrochloride
[29], or exogenously with tritiated borohydride [30],
and puri¢ed with antibodies to the mucin. Released
labelled O-glycans were then analysed by comparison
to standards in Dionex chromatography. The inter-
nally labelled mucin was precipitated from T47D
cells using a polyclonal antibody to the cytoplasmic
tail which recognises all glycoforms [31]. The exoge-
Fig. 2. Pathways of O-glycosylation of MUC1 in breast tissue.
In normal mammary epithelial cells core 1 glycans are con-
verted to core 2 by the action of core 2 L1,6GlcNAcT. In
breast carcinomas, this conversion is reduced, resulting in core
1-based structures being found on MUC1.
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nously labelled MUC1 was puri¢ed from the breast
cancer cell line, BT20, using immuno-a⁄nity chro-
matography and a monoclonal antibody (DF3) di-
rected to an epitope in the tandem repeat which
could select for certain glycoforms. In both cases,
however, the structure of the O-glycans was found
to be core 1 and not core 2 based. In the case of
T47D, 59% of the glycans had the structure of the
disaccharide GalL1,3 GalNAc, i.e the T blood group
antigen, 33% consisted of sialyl T, while a small pro-
portion, 8%, was unsubstituted GalNAc (Tn). These
direct analyses con¢rm the earlier work of the late
George Springer, who demonstrated the appearance
of the T epitope in breast cancer [32] and used a
preparation of erythrocytes expressing this antigen
in the treatment of breast cancer patients. The
more recent data related to MUC1 identify a core
protein which carries this O-glycan. The sialyl Tn
epitope (NeuAcK2,6 GalNAc) has been reported to
be speci¢cally expressed in several cancers, including
gastric and breast, and has been used, coupled to a
carrier protein as an immunogen for cancer patients
(see below). However, sialyl Tn was not found in any
quantity in the studies analysing the O-glycans on
MUC1 mucin from breast cancer cell lines.
2.5. Correlation in changes of glycosyltransferase
activities with changes in O-glycan structure in
breast cancer
An examination of Fig. 2 shows that core 1 can be
a substrate for an enzyme leading to chain extension
via core 2 or for an enzyme which, by adding sialic
acid to core 1 to form sialyl T, terminates chain
extension. Analysis of the activity of the enzymes
catalysing these reactions in extracts of normal and
malignant breast epithelial cell lines showed that the
K-2,3-sialyl-transferase activity was increased 8^10-
fold in three breast cancer cells lines relative to the
normal cell line (MTSV1^7), while the C2GnT en-
zyme activity was absent in two of the breast cancer
cell lines (T47D and BT20) and reduced by 50% in a
third [33]. Observations at the mRNA level revealed
that C2GnT mRNA was essentially absent in the
T47D and BT20 lines. However, C2GnT mRNA
was paradoxically elevated in the MCF-7 line sug-
gesting translational/post-translational control. Anal-
ysis of C2GnT promoter activity via 5P-untranslated
regions reveal no signi¢cant alternative promoter
usage in any of the cell lines (Dalziel et al., unpub-
lished observations) although evidence for multiple
promoters was detected with the mouse C2GnT
[34].
Clearly in measuring the activity of a cell extract
several enzymes may be involved in the same reac-
tion. In the case of the activity, catalysing the for-
mation of core 2 from core 1, it is likely that the L
enzyme which has been cloned [35] is being measured
as the activity of the M enzyme which also catalyses
the formation of core 4 [36], was not detected in
these cells [33]. In the case of the sialyltransferase,
there are at least three enzymes which could theoret-
ically catalyse the formation of the addition of sialic
acid in K2,3 linkage to GalL1,3-GalNAc [37,38].
However, in situ analysis of tumour sections with a
speci¢c ST3Gal I probe [39] shows a marked increase
in expression of this speci¢c sialyltransferase in
breast cancers. Signi¢cantly the increased expression
correlated with both the invasiveness of the tumour,
and with the expression of the SM3 epitope.
The levels of mRNA coding for the c2GnT were
not consistently decreased in the breast cancers ex-
amined by in situ hybridisation with the C2GnT
probe. However, if the two enzymes are in a similar
position in the Golgi then increasing the activity of
one could compete e¡ectively for the common sub-
strate, i.e. core 1. The availability of the cloned genes
makes it possible to transfect cells and thus (a) alter
the level of enzyme expressed and (b) by using a gene
tagged with an epitope recognised by an antibody,
localise the enzyme in the Golgi apparatus. Such ex-
periments have shown that the ST3Gal I sialyltrans-
ferase is mainly located in the medial/trans Golgi
with some being detected in the cis Golgi compart-
ment, and that over expressing the enzyme in the
normal MTSV1^7 cells results in a reduction in the
core 2 based structures added to MUC1 [40]. Local-
isation studies with the C2GnT suggest that it is
mainly in the cis/medial Golgi; MUC1 from
C2GnT transfected T47D cells has core 2 structures
(instead of the core 1 structures present in the un-
transfected cells) (Whitehouse, Dalziel, Burchell and
Taylor-Papadimitriou, manuscript in preparation).
Signi¢cantly, the T47D cells over expressing the
core 2 enzyme lose expression of the SM3 epitope
which is exposed in the untransfected cells. Thus,
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although the changes in the composition of O-gly-
cans added to MUC 1 in breast cancer may not be
completely explained by the increase in sialyltransfer-
ase activity, (since a high proportion of the O-gly-
cans on the cancer mucin are not sialylated), the
enzyme does appear to compete with the core 2 en-
zyme for core 1 and high levels of activity are asso-
ciated with the expression of the tumour-speci¢c
SM3 epitope.
It should be noted, of course, that the changes in
expression of glycosyltransferases seen in breast can-
cer will a¡ect the glycosylation not only of MUC1,
but also of other molecule undergoing mucin-type O-
glycosylation.
2.6. Changes in glycosylation of MUC1 in other
cancers
Human colon cancer is associated with antigenic
and structural changes in mucin type O-glycan car-
bohydrate chains. In particular loss of O-glycans has
been reported [41]. Changes in the carbohydrate epit-
opes carried on MUC1 have been detected in colon
cancer by purifying components from cancer cell
lines which express the epitopes sialyl Lex and Lea
which are not well expressed in the normal colon
[42]. The full structures have been analysed, but the
direct comparison with the full structures on the can-
cer associated mucin carried on the mucin produced
by normal colon has not been done. However, it is
clear that the SM3 epitope, which is absent from
normal colon can be exposed in some colon cancers
[8]. This epitope also appears in ovarian cancers [8]
and gastric carcinomas [43], suggesting some modi¢-
cation of the side chains in these diseases.
The increased expression of the sialyl Lex epitope
in colon cancer is of interest as this epitope is ex-
pressed on the glycoform of the selectin ligand
PSGL1 which interacts with P and E selectin. Data
from Hansson and colleagues [42] show that MUC1
carrying sialyl Lea and Lex which was puri¢ed from a
colon carcinoma cell line, inhibited the adhesion of a
leucocyte cell line to cells transfected with E-selectin
(see below). Interestingly, the increase of sialyl
Lewisx expression in colon carcinomas has been at-
tributed to a decrease in O-acetylation of mucin-
bound sialyl Lex which occurs in colon carcinomas
[44].
3. Expression of MUC1 and malignant progression
3.1. E¡ects of MUC1 expression on the behavioural
properties of cancer cells
3.1.1. E¡ects on cell interactions and tumourogenicity
The changes in expression and post-translational
modi¢cation of MUC1 has stimulated investigations
into whether this a¡ects the behaviour of cancer
cells, particularly in relation to interactions with oth-
er cells and with the extracellular matrix. In the nor-
mal glandular epithelial cell, MUC1 expression is
limited to the apical surface bordering a lumen. In
cancer cells however, which have lost polarity, the
mucin is expressed all over the surface. Because of
its rod-like structure, the molecule extends more than
100^200 nm above the surface, which is 5^10-fold the
length of most membrane molecules. By virtue of the
high level of sialic acid, MUC1 is also negatively
charged and cells expressing high levels may repel
each other. Such repulsive e¡ects have been demon-
strated by showing that MUC1 transfectants show
reduced aggregation as compared to the non-express-
ing parental cells [45] and interactions with the ex-
tracellular matrix are also inhibited [46]. With E-cad-
herin-mediated cell interactions, MUC1 has been
reported to be inhibitory (in L cells transfected
with E-cadherin and MUC1) [47], and to enhance
adhesion by interacting with L-catenin [48].
In considering the e¡ects of MUC1 on cell^cell
interactions, it is clear that without speci¢c interac-
tions, for example with a lectin molecule, the long
highly charged molecule can easily result in repulsion
between cells. These inhibitory e¡ects on cell inter-
actions appear to depend on both the large size of
the molecule and the negative charge [46,47]. How-
ever, where a speci¢c interaction is possible, for ex-
ample a particular carbohydrate epitope binding to a
lectin, then cell interactions may be enhanced. Thus,
MUC1 has been reported to be a ligand for ICAM1
expressed by endothelial cells [49] and to enhance
antigen presentation to T-cells, possibly operating
through a lectin interaction [50]. Furthermore,
MUC1 has been shown to be a ligand for sialoadhe-
sin, a macrophage restricted adhesion molecule,
which speci¢cally binds Neu5AcK2,3Gal and so
may be involved in recruiting macrophages into the
tumour site [51].
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When the glycosylation pattern of the mucin is
changed in carcinomas, resulting in the production
of di¡erent glycoforms, such carbohydrate dependent
interactions will be a¡ected. The O-glycans on the
cancer mucin will also vary with the speci¢c carcino-
ma, so that while selectin ligands may appear on
MUC1 produced by colon carcinomas, these may
not be present in breast cancers. How the surface
MUC1 on cancer cells may in£uence metastatic pro-
gression is not clear, although in Muc-1 null mice,
mammary tumour progression has been reported to
be delayed [52].
3.1.2. MUC1 expression and immune responses
Cell^cell interactions in the context of cellular im-
mune responses are of particular interest, since
MUC1 is under intensive study as a possible immu-
nogen for immunotherapy of some cancer patients.
Before considering these studies, it is appropriate to
consider brie£y the framework of the di¡erent com-
partments of the immune response to see how these
might be e¡ectively recruited by MUC1 based immu-
nogens to kill cancer cells.
The immune system was developed to reject invad-
ing pathogens, be these extracellular as with most
bacteria and fungi, or intracellular parasites such as
viruses. In vertebrates, there are two major compart-
ments namely the ‘innate’ immune response and the
‘adaptive’ immune response. Lower organisms use
only innate immunity where molecules with a speci¢c
structural pattern, characteristic of a class of patho-
gens (pathogen associated molecular patterns or
PAMPs) are recognised [53]. Examples of these are
the mannans of yeasts, lipopolysacharides of Gram-
negative bacteria or bacterial DNA which contains
unmethylated CpG dinucleotides [54]. Many of these
PAMPs are rich in carbohydrates and can interact
with lectins. Their interaction with lectins on antigen
presenting cells (APCs) activates the cells to increase
expression of molecules (MHC, co-stimulatory mol-
ecules and cytokines) required to stimulate the adap-
tive immune response mediated by T-cells and B-cells
(see Fig. 3). These cells recognise small domains or
‘epitopes’ which, in the case of B-cells are present in
a large molecule or antigen and recognised by surface
immunoglobulin. T-cells, however, recognise peptides
derived from the larger molecule which are presented
either by MHC class I molecules, which activate the
T-cell receptor (TCR) of CD8+ cytotoxic T-cells
(CTL), or by MHC class II molecules which activate
the TCR of CD4+ helper T-cells. Depending on the
cytokines produced, the adaptive immune response
may be geared towards a Th1 response where CTL
develop, or towards a Th2 response with a bias to-
wards the induction of antibodies. It is generally
thought that a Th1 response is required for e¡ective
rejection of cancer cells, although a role for antibod-
ies is not excluded.
In considering MUC1 as an antigen, it is clear that
where the response is to the whole molecule, the
glycoform is of paramount importance. This will ap-
ply to the antibody response, and to lectin mediated
interactions with the e¡ector cells of the immune
system. MUC1 is a highly repetitive molecule, carry-
ing multiple O-glycans which are di¡erent in the can-
cer mucin. It is therefore not unlikely that this par-
ticular glycoform may be capable of acting as a
PAMP as well as enhancing cell^cell interactions.
Whether the presentation of peptides by MHC mol-
ecules is occurring and whether this is a¡ected by
glycosylation remains to be clari¢ed. Theoretically,
class II presentation could be a¡ected since exoge-
nous antigen is taken up and degraded. However,
since class I molecules are loaded in the ER before
O-glycosylation is initiated, it would seem unlikely
that peptides carrying O-glycans can be presented.
The exception may be presentation by dendritic cells
Fig. 3. Recognition of a pathogen by APCs through innate im-
munity leads to activation of adaptive immunity.
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(DCs) which can direct antigen taken up exogenously
to the cytoplasm.
As indicated above, the MUC1 mucin was ¢rst
recognised as a tumour-associated antigen by virtue
of its dominance in inducing antibodies in mice. The
¢rst indication that the molecule may be immuno-
genic in humans came from the observations of
Finn and colleagues who isolated cytotoxic T-cells
(CTL) from breast and ovarian cancer patients which
killed MUC1 expressing cells in a non-HLA re-
stricted fashion [55]. These studies indicated that
only the carcinoma associated glycoform was recog-
nised by the CTL [56] and it was suggested that the
intact molecule made multiple interactions with the
T-cell receptors (TCR), the important epitope being
found within the tandem repeat [57]. Only later was
it reported that antibodies recognising sequences in
the tandem repeat are also found in cancer patients
[58,59]. These original observations have been fol-
lowed by studies from several groups working with
mouse models and human PBL (peripheral blood
leucocytes) attempting to de¢ne the cellular re-
sponses to MUC1. Classical MHC restricted re-
sponses to epitopes within the tandem repeat have
been reported for most of the common mouse strains
[60]. HLA restricted CTL have also been isolated
from HLA-A2 transgenic mice [61] while human
CTL able to recognise MUC1 peptide epitopes pre-
sented by HLA-A11 have also been recognised [62].
Proliferative responses to the MUC1 tandem repeat
peptide possibly representing a helper T-cell response
have been reported [63].
In contrast to the studies directed towards under-
standing and enhancing the immune response to
MUC1, inhibitory e¡ects of the mucin on T-cell re-
sponses have been reported [64,65]. Clearly, the pos-
sibility of the dual function of repelling cells by the
highly charged extended mucin or enhancing adhe-
sion via lectin interactions bring a complexity to the
function of the molecule in the context of cell inter-
actions which is not easily resolved.
4. MUC1 in immunotherapy of breast cancer patients
4.1. Antibody therapy
The monoclonal antibodies which have been raised
to MUC1 have been available since the early 1980s
and have been used in the clinic mainly as carriers of
radioactive elements. The HMFG1 antibody (origi-
nally called 1.10.F3) was developed in 1981 and has
been used mainly in ovarian cancer patients to deliv-
er a high dose of yttrium to the peritoneum [66]. In
patients with minimal residual disease after chemo-
therapy, a signi¢cant survival bene¢t was seen as
compared to historical controls. The results are of
su⁄cient interest to have prompted a phase III multi-
centre trial in these patients which is now ongoing.
Recently, a small trial has been initiated with unla-
belled humanised HMFG1 antibody for adjuvant
therapy of breast cancer patients (D. Miles, personal
communication) since studies in other cancers have
shown that antibody alone can inhibit metastatic
growth [67]. Another monoclonal antibody, BrE-3
labelled with 111In has been used to target breast
carcinomas [68], and more recently 111In and 90Y-
labelled BrE-3 has also been used in the treatment
of breast cancer [69]. In this study of six patients,
three showed transient clinical response, thus war-
ranting further studies. Imaging studies with radio-
labelled antibodies, particularly ovarian cancer pa-
tients with the SM3 antibody have shown that ma-
lignant tumours can be distinguished from benign
lesions. This form of screening could be implemented
in high-risk patients, for example, those with a
strong family background of disease. Some success
has also been observed in detecting breast cancer
cells in involved lymph nodes in breast cancer pa-
tients [70]. Finally, antibodies to MUC1 are also
used in breast cancer management to detect MUC1
in serum in an attempt to detect relapse before clin-
ical symptoms appear.
Antibodies to MUC1 initiated interest in the
MUC1 mucin and also led to the cloning of the
gene coding for the core protein. Now that the mucin
is well characterised, interest in using MUC1 based
formulations for active speci¢c immunotherapy of
carcinomas expressing the molecule has developed.
There are several reasons why the mucin is being
seriously considered as a target antigen, not least of
which is the fact that both cellular and humoral re-
sponses have been observed in cancer patients.
Changes in intracellular distribution of MUC1 which
is apical in normal glandular epithelia, but distrib-
uted all over the surface of the cancer cell, would
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allow selectivity in any killing dependent on reaction
with the whole molecule. As indicated above, the
glycoform of the molecule has to be considered.
4.2. Active speci¢c immunotherapy based on MUC1:
animal models
Before clinical studies can be initiated, some form
of preclinical testing in animal models is necessary.
To this end, syngeneic and transgeneic mouse models
have been developed [71^73]. Syngeneic models have
been used to investigate the e⁄cacy of immunogens
based on MUC1, including naked DNA [71], viral
vectors [74], peptides [75] and liposome encapsula-
tion of peptides [76]. Using MUC1 transgenic mice
it has been shown that tolerance to the mucin can be
overcome without inducing autoimmunity [77,78].
However, even when using MUC1 transgenic mice
the immune response observed is representative of
the murine repertoire. Studies using HLA-A2 trans-
genic mice have shown that there are functional
CTL-A2 epitopes within MUC1 [61] and probably
the next generation of preclinical testing should in-
volve the use of MUC1, HLA double transgenic
mice. However, even in this model other compart-
ments of the immune response, eg receptors on
APCs are still murine and so no animal model can
truly predict the response that will be observed in
humans.
4.3. Active speci¢c immunotherapy based on MUC1:
clinical studies
Some of the humoral and cytotoxic immune re-
sponses to MUC1 in cancer patients are known to
be directed to speci¢c sequences in the tandem re-
peat. As a result, and because there are many prag-
matic advantages in using relative short de¢ned
amino acid sequences, the clinical studies involving
the use of peptides as the immunogen have con-
centrated on the tandem repeat of MUC1. Phase I
studies have reported the use of tandem repeat
peptides coupled to diphtheria toxoid [79], BCG
[80] or KLH [81]. In the Biomira trial [80], class I
restricted CTL were demonstrated after immunisa-
tion with 16 amino acids from the tandem repeat
coupled to KLH, and increase in CTL precursor fre-
quency has been reported when patients have been
immunised with ¢ve tandem repeats mixed with BCG
[80].
One formulation that looked very promising in the
animal model was the use of a MUC1 tandem repeat
fusion protein coupled to oxidised mannan, which
should target mannose receptors on APCs. However,
although a predominantly CTL response was dem-
onstrated in mice [82], early clinical trials conducted
in patients with advanced breast and colorectal can-
cer show that in the clinical setting the predominant
response was humoral, with few CTL being observed
[83]. This apparent discrepancy highlights the limita-
tions of translating studies in animal models into the
clinical setting. The di¡erent response in humans is
attributed to the presence of cross reactive antibodies
present in humans (but not in mice) which form an
immune complex with the antigen, which in turn in-
duces a Th2 type response [84].
The use of tandem repeat peptides as immunogens
has the disadvantage that the response is being re-
stricted to one domain of the mucin. One way to
overcome this is the use of viral vectors carrying
DNA encoding MUC1 which also have the advant-
age of infecting the cells and so targetting MUC1
into the class I pathway. A recombinant vaccinia
virus carrying cDNA for MUC1 and for IL-2
(VV-MUC1/IL2) has been constructed [85] and
shown to induce CTL in mouse models. This con-
struct has been used in a phase I study of patients
with advanced breast cancer. Immunisation was not
associated with signi¢cant toxicity and immune re-
sponses were detected in some patients [86]. A phase
II multicentre trial using the VV-MUC1/IL2 con-
struct in patients with metastatic breast cancer is
now in progress.
A direct way to exploit the aberrant glycosylation
of MUC1 for immunotherapy is the use of tumour-
associated carbohydrate antigens which are found on
MUC1, but may also be carried on other glycopro-
teins. A prospective, randomised clinical trial using
STn in patients with breast cancer has recently been
reported [87]. All patients were immunised subcuta-
neously with STn conjugated to KLH, with DETOX
adjuvant. Patients were also randomised to receive
before the ¢rst immunisation either low dose intra-
venous cyclophosphamide or no or oral cyclophos-
phamide [88]. This was because it has been suggested
that soluble antigen in the circulation can be immu-
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nosuppressive and that at least in mice, this can be
overcome by pretreatment with low dose cyclophos-
phamide [89,90]. The treatment had minimal toxicity
and the highest antibody titres were in patients pre-
treated with intravenous cyclophosphamide. Further-
more, the median survival for the group pretreated
with i.v. cyclophosphamide was signi¢cantly longer
than that for the other groups. As there were no
di¡erences between the groups in terms of the natu-
ral history of their disease or the number and type of
previous treatments, the results suggest a therapeutic
e¡ect for pretreatment with i.v. cyclophosphamide
followed by immunisation with STn-KLH. A large
multicentre trial comparing i.v. cyclophosphamide
and STn-KLH/DETOX-B with i.v. cyclophospha-
mide and KLH/DETOX-B in the treatment of pa-
tients with breast cancer is about to commence.
5. Summary
In summary, MUC1 is upregulated and aberrantly
glycosylated in many carcinomas. It is useful as a
model glycoprotein in the study of glycosylation
changes associated with malignancy, as changes in
activities of glycosyltransferases have been directly
correlated with changes in the structure of glycans
attached to MUC1. Furthermore, it has many char-
acteristics that make it an excellent candidate mole-
cule for active speci¢c immunotherapy, and this is
re£ected by the number and scope of early clinical
studies that have been initiated.
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